Table 1.

Baseline information of the enrolled studies.

Study	Sex (M/F)		Population		Age(mean or range)		Duration oftreatment	Mainoutcome
	T	C	T	C	T	C
Hu et al., 2012 [23]	17/2	18/2	19	20	50.4 ± 12.8	51.4 ± 14.1	30 days	AHI, LSaO2, ESS
Wang et al., 2013 [24]	32/8	36/4	40	40	47.02 ± 14.24	43.63 ± 12.16	3 months	AHI, LSaO2, ESS
Chen et al., 2015 [25]	20/10	21/9	30	30	68.2 ± 5.9	65.0 ± 6.3	12 weeks	AHI、LSaO2、ESS
Feng et al., 2015 [26]	26/4	27/3	30	30	43.34 ± 6.42	42.19 ± 7.49	12 weeks	AHI, ESS
Lv et al., 2017 [27]	19/6	20/5	25	25	52.5 ± 5.4	51.2 ± 5.1	20 days	AHI, LSaO2
Liu et al., 2017 [28]	26/6	23/9	32	32	46.3 ± 2.2	47.5 ± 3.6	1 months	AHI
Gui et al., 2017 [29]	21/29	20/30	50	50	54.19 ± 4.26	54.26 ± 3.19	4 weeks	AHI, LSaO2, ESS
Yin et al., 2017 [30]	34/11	33/12	45	45	52.49 ± 3.27	52.68 ± 3.59	3 months	AHI, ESS
Xu et al., 2018 [31]	22/6	23/4	28	27	42.80 ± 11.94	43.72 ± 13.96	12 weeks	AHI, LSaO2
Lu, 2018 [32]	38/2	39/1	40	40	43.19 (35–58)	42.86 (32–55)	8 weeks	AHI
Jin et al., 2019 [33]	20/8	21/7	28	28	42.25 ± 13.60	43.11 ± 12.09	1 months	AHI, LSaO2, ESS
Yang et al., 2019 [34]	32/8	34/6	40	40	40.2 ± 10.1	41.3 ± 11.4	30 days	AHI, LSaO2, ESS
Liu et al., 2019 [35]	20/12	22/10	32	32	58.1 ± 5.0	59.0 ± 5.0	4 weeks	AHI, LSaO2, ESS

Note. M, male; F, female; T, treatment group; C, control group; N.R, not reported.